Antibody Combination Therapy Market: By Type, By Therapeutic Type, By Mode of Administration, By Distribution Channel And Geography

Antibody Combination Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Murine Antibodies, Humanized Antibodies, Chimeric Antibodies), By Therapeutic Type (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others), By Mode of Administration (Parenteral, Enteral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) And Region

Antibody Combination Therapy Market size was valued at US$ 236.2 billion in 2023 and is poised to grow at a CAGR of 12.8% from 2024-2030. Foods that are subjected to technological modifications either for protection or for changing over into prepared-to-utilize/eat nourishments, disposing of relentless family unit strategies, are called antibody combination therapy. A portion of the cases is processed blends, dried-out nourishments, pasta items, canned food, confectioneries, pastry shops, dairy items, and breakfast nourishments. Manufacture of Antibody Combination Therapy requires innovative application and apparatus, and thus, Antibody Combination Therapy is costly. Organizations are embracing different techniques, for example, an extension of product features to maintain the powerfully developing antibodies advertise.

The worldwide market is relied upon to witness great development over the conjecture time frame. However, the mind-boggling expense of treatment and symptoms related to antibody treatment can upset the development of the market. There has been an expansion in R&D exercises by numerous pharmaceutical and biotechnology organizations to create progressed biologics including monoclonal antibodies. Spotlight on R&D is a basic system to drive long-haul development of the organization. A few pharmaceutical and biotechnology organizations are experiencing associations and joint efforts to pick up initiatives in the division. For example,

Key Developments:

  • In June 2016, Novartis and Xencor Inc., went into a vital joint effort and authorizing assention. The significant organizations are embraced different methodologies activities, for example, new product advancement, mergers and acquisitions, joint efforts, and provincial extension for serving the neglected needs of their clients.

Antibody Combination Therapy Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.8%

Largest Market

North America

Fastest Growing Market

Asia-Pacific

Antibody Combination Therapy Market Dynamics

Worldwide Antibody Combination Therapy Market is principally determined by components, for example, consistent dispatch of creative items, high appropriation rate of helpful antibodies in cost-touchy markets, brisk endorsement by administrative specialists for leap forward treatments, ascend in interminable diseases attributable to populace move and expanding life span, accessibility of economical biosimilar counter acting agent therapeutics, and reception of symptomatic antibodies.

Antibody Combination Therapy Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 236.2 billion

Market CAGR

12.8%

By Therapeutic Type

  • Breast Cancer
  • Blood cancer
  • Liver Cancer
  • Brain cancer
  • Colorectal Cancer
  • Others

By Mode of Administration

  • Parenteral
  • Enteral
  • Others

By Type

  • Murine Antibodies
  • Humanized Antibodies
  • Chimeric Antibodies

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Key Features of the Report

  • The antibody combination therapy market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

Frequently Asked Questions

The antibody combination therapy market size was valued at US$ 231 billion in 2023 and is poised to grow at a CAGR of 12.8% from 2024-2030

The antibody combination therapy market key players are: Merck & Co. Inc. (U.S.) Hoffmann-La Roche AG (Switzerland) Spectrum Pharmaceuticals U.S.) Eli Lilly and Company (U.S.) Amgen Inc. (U.S.) Bristol-Meyer Squibb (U.S.) Sanofi S.A. (France) AstraZeneca plc (U.S.)

The antibody combination therapy market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Antibody Combination Therapy Market Introduction 
2.1.Global Antibody Combination Therapy Market  - Taxonomy
2.2.Global Antibody Combination Therapy Market  - Definitions
2.2.1.Therapeutic Type
2.2.2.Mode of Administration
2.2.3.Type
2.2.4.Distribution Channel
2.2.5.Region
3.Global Antibody Combination Therapy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Antibody Combination Therapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Antibody Combination Therapy Market  By Therapeutic Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Breast Cancer
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Blood cancer
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Liver Cancer
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Brain cancer
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Colorectal Cancer
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6.Global Antibody Combination Therapy Market  By Mode of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Parenteral
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Enteral
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Others
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Antibody Combination Therapy Market  By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Murine Antibodies,
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Humanized Antibodies,
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Chimeric Antibodies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Antibody Combination Therapy Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital Pharmacy,
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacy, and
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacy
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Antibody Combination Therapy Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Therapeutic Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Breast Cancer
10.1.2.Blood cancer
10.1.3.Liver Cancer
10.1.4.Brain cancer
10.1.5.Colorectal Cancer
10.1.6.Others
10.2.  Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Parenteral
10.2.2.Enteral
10.2.3.Others
10.3.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Murine Antibodies,
10.3.2.Humanized Antibodies,
10.3.3.Chimeric Antibodies
10.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacy,
10.4.2.Retail Pharmacy, and
10.4.3.Online Pharmacy
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Therapeutic Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Breast Cancer
11.1.2.Blood cancer
11.1.3.Liver Cancer
11.1.4.Brain cancer
11.1.5.Colorectal Cancer
11.1.6.Others
11.2.  Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Parenteral
11.2.2.Enteral
11.2.3.Others
11.3.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Murine Antibodies,
11.3.2.Humanized Antibodies,
11.3.3.Chimeric Antibodies
11.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacy,
11.4.2.Retail Pharmacy, and
11.4.3.Online Pharmacy
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Therapeutic Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Breast Cancer
12.1.2.Blood cancer
12.1.3.Liver Cancer
12.1.4.Brain cancer
12.1.5.Colorectal Cancer
12.1.6.Others
12.2.  Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Parenteral
12.2.2.Enteral
12.2.3.Others
12.3.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Murine Antibodies,
12.3.2.Humanized Antibodies,
12.3.3.Chimeric Antibodies
12.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacy,
12.4.2.Retail Pharmacy, and
12.4.3.Online Pharmacy
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Therapeutic Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Breast Cancer
13.1.2.Blood cancer
13.1.3.Liver Cancer
13.1.4.Brain cancer
13.1.5.Colorectal Cancer
13.1.6.Others
13.2.  Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Parenteral
13.2.2.Enteral
13.2.3.Others
13.3.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Murine Antibodies,
13.3.2.Humanized Antibodies,
13.3.3.Chimeric Antibodies
13.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacy,
13.4.2.Retail Pharmacy, and
13.4.3.Online Pharmacy
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Antibody Combination Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Therapeutic Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Breast Cancer
14.1.2.Blood cancer
14.1.3.Liver Cancer
14.1.4.Brain cancer
14.1.5.Colorectal Cancer
14.1.6.Others
14.2.  Mode of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Parenteral
14.2.2.Enteral
14.2.3.Others
14.3.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Murine Antibodies,
14.3.2.Humanized Antibodies,
14.3.3.Chimeric Antibodies
14.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacy,
14.4.2.Retail Pharmacy, and
14.4.3.Online Pharmacy
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Merck & Co. Inc. (U.S.)
15.2.2.Hoffmann-La Roche AG (Switzerland)
15.2.3.Spectrum Pharmaceuticals U.S.)
15.2.4.Eli Lilly and Company (U.S.)
15.2.5.Amgen Inc. (U.S.)
15.2.6.Bristol-Meyer Squibb (U.S.)
15.2.7.Sanofi S.A. (France)
15.2.8.AstraZeneca plc (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Merck & Co. Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Spectrum Pharmaceuticals U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Bristol-Meyer Squibb (U.S.)
  • Sanofi S.A. (France)
  • AstraZeneca plc (U.S.)

Related Industry Reports